指南与共识真菌感染

血液系统恶性肿瘤患者侵袭性真菌病的初级预防:德国血液与肿瘤医学学会(DGHO)感染性疾病工作组(AGIHO)2022年推荐更新

Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
指南 / 共识 · J Antimicrob Chemother · 2023-01-01

该指南基于截至2021年9月的文献更新2017年版推荐。对长期中性粒细胞减少(<500 cells/μL持续>7天)患者给予抗真菌预防的强推荐不变,泊沙康唑仍为 mould-active 预防首选。与2017版相比,艾沙康唑和伏立康唑的推荐强度由轻度支持改为中度支持;首次纳入非药物措施推荐。

要点

  • 长期中性粒细胞减少(<500 cells/μL持续>7天)患者给予抗真菌预防为强推荐,泊沙康唑为首选。
  • 与2017版相比,艾沙康唑和伏立康唑的推荐强度由轻度支持改为中度支持。
  • 米卡芬净可获中度强度推荐用于血液系统恶性肿瘤患者。

核心结论

  • 长期中性粒细胞减少(<500 cells/μL持续>7天)的血液系统恶性肿瘤患者给予抗真菌预防的强推荐不变,泊沙康唑仍为 mould-active 预防的首选药物。

研究设计与样本

  • 德国血液与肿瘤医学学会(DGHO)感染性疾病工作组(AGIHO)基于截至2021年9月发表的文献更新2017年版抗真菌预防推荐。

主要发现

  • 与2017版相比,艾沙康唑和伏立康唑的推荐强度由轻度支持改为中度支持。
  • 发表的证据允许以中度强度推荐米卡芬净用于血液系统恶性肿瘤患者。
  • 目前无证据支持新型抗真菌药物在临床实践中用于预防。

关键数值与推荐

  • 对长期中性粒细胞减少(<500 cells/μL持续>7天)的血液系统恶性肿瘤患者给予抗真菌预防为强推荐。
  • 泊沙康唑仍为这些患者 mould-active 预防的首选药物。
  • 艾沙康唑和伏立康唑获中度支持推荐(较2017版轻度支持升级)。
  • 米卡芬净获中度强度推荐用于血液系统恶性肿瘤患者。
  • 工作组推荐:与强CYP3A4抑制性抗真菌药联用时,应降低维奈克拉剂量。

临床怎么用

  • 对长期中性粒细胞减少(<500 cells/μL持续>7天)的血液系统恶性肿瘤患者给予抗真菌预防(强推荐)。
  • 泊沙康唑作为这些患者 mould-active 预防的首选药物。
  • 艾沙康唑、伏立康唑和米卡芬净可用于血液系统恶性肿瘤患者的预防(中度支持推荐)。
  • 与强CYP3A4抑制性抗真菌药联用时,应降低维奈克拉剂量(工作组推荐)。
  • 非药物措施推荐包括使用高效空气颗粒过滤器(HEPA)、吸烟、施工期间措施及中性粒细胞减少饮食。

局限性

  • CAR-T细胞治疗或急性髓系白血病(AML)新型靶向治疗患者的数据不足,无法给出常规抗真菌预防的一般推荐。
  • 目前无证据支持新型抗真菌药物在临床实践中用于预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update the 2017 antifungal prophylaxis recommendations of the German Society of Haematology and Medical Oncology (DGHO). The strong recommendation to administer antifungal prophylaxis in patients with HM with long-lasting neutropenia, i.e. <500 cells/μL for >7 days remains unchanged. Posaconazole remains the drug of choice for mould-active prophylaxis in these patients. Novel treatment options in HM, such as CAR-T-cell treatment or novel targeted therapies for acute myeloid leukaemia (AML) were considered, however, data are insufficient to give general recommendations for routine antifungal prophylaxis in these patients. Major changes regarding specific recommendations compared to the 2017 edition are the now moderate instead of mild support for the recommendations of isavuconazole and voriconazole. Furthermore, published evidence on micafungin allows recommending it at moderate strength for its use in HM. For the first time we included recommendations for non-pharmaceutical measures regarding IFD, comprising the use of high-efficiency particulate air (HEPA) filters, smoking, measures during construction work and neutropenic diets. We reviewed the impact of antifungal prophylaxis with triazoles on drug-drug interactions with novel targeted therapies that are metabolized via cytochrome p450 where triazoles inhibit CYP3A4/5. The working group recommends reducing the dose of venetoclax when used concomitantly with strong CYP3A4 inhibiting antifungals. Furthermore, we reviewed data on the prophylactic use of novel antifungal agents. Currently there is no evidence to support their use in a prophylactic setting in clinical practice.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Stemler J, Mellinghoff SC, Khodamoradi Y, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023. PMID: 37311136. doi:10.1093/jac/dkad143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。